Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NYSE:BHC NASDAQ:IONS NASDAQ:JAZZ NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$175.71+4.5%$168.04$111.09▼$183.00$10.28B0.38505,218 shs838,000 shsBHCBausch Health Cos$6.59-1.6%$5.39$3.96▼$9.85$2.48B0.412.60 million shs1.05 million shsIONSIonis Pharmaceuticals$42.83+3.6%$35.95$23.95▼$52.34$6.58B0.231.61 million shs1.69 million shsJAZZJazz Pharmaceuticals$111.60+2.3%$108.60$95.49▼$148.06$6.60B0.32825,805 shs565,575 shsRAREUltragenyx Pharmaceutical$41.44+5.1%$36.82$29.59▼$60.37$3.73B0.26849,292 shs2.60 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+4.48%+1.51%+1.48%+22.59%+28.77%BHCBausch Health Cos-1.79%-7.31%+35.04%+51.32%-8.41%IONSIonis Pharmaceuticals+3.60%-1.74%+16.51%+60.35%-8.95%JAZZJazz Pharmaceuticals+2.26%+1.53%-0.24%+9.36%+10.97%RAREUltragenyx Pharmaceutical+5.12%+5.02%+11.88%+24.97%-1.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.5096 of 5 stars4.53.00.00.02.01.70.6BHCBausch Health Cos3.6927 of 5 stars1.93.00.04.02.33.30.6IONSIonis Pharmaceuticals4.5907 of 5 stars4.42.00.03.02.73.30.6JAZZJazz Pharmaceuticals4.8712 of 5 stars4.51.00.04.02.13.32.5RAREUltragenyx Pharmaceutical3.9822 of 5 stars3.51.00.03.82.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$220.6725.59% UpsideBHCBausch Health Cos 1.83Reduce$7.3010.77% UpsideIONSIonis Pharmaceuticals 2.78Moderate Buy$58.2536.00% UpsideJAZZJazz Pharmaceuticals 2.92Moderate Buy$184.0064.87% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$87.00109.94% UpsideCurrent Analyst Ratings BreakdownLatest BHC, JAZZ, IONS, ASND, and RARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.006/11/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.006/3/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M27.29N/AN/A($1.88) per share-93.46BHCBausch Health Cos$9.73B0.25$7.57 per share0.87($0.89) per share-7.40IONSIonis Pharmaceuticals$705M9.67N/AN/A$3.73 per share11.48JAZZJazz Pharmaceuticals$4.07B1.66$31.09 per share3.59$67.72 per share1.65RAREUltragenyx Pharmaceutical$560.23M6.99N/AN/A$2.76 per share15.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A732.13N/A-93.22%N/A-33.29%9/2/2025 (Estimated)BHCBausch Health Cos-$46M-$0.11N/A1.41N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M$7.5014.885.964.7111.86%26.62%9.14%7/30/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)Latest BHC, JAZZ, IONS, ASND, and RARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IONSIonis Pharmaceuticals$0.19N/AN/AN/AN/AN/A8/7/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27N/AN/AN/AN/AN/A7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A7/30/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61N/AN/AN/A$1.05 billionN/A5/6/2025Q1 2025JAZZJazz Pharmaceuticals$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71BHCBausch Health CosN/A1.350.97IONSIonis Pharmaceuticals2.639.669.62JAZZJazz Pharmaceuticals1.283.382.97RAREUltragenyx PharmaceuticalN/A2.402.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABHCBausch Health Cos78.65%IONSIonis Pharmaceuticals93.86%JAZZJazz Pharmaceuticals89.14%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BHCBausch Health Cos8.05%IONSIonis Pharmaceuticals2.60%JAZZJazz Pharmaceuticals4.30%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million155.02 millionOptionableJAZZJazz Pharmaceuticals2,80060.51 million57.91 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableBHC, JAZZ, IONS, ASND, and RARE HeadlinesRecent News About These CompaniesUltragenyx stock plummets after OI drug study continues to final analysisJuly 9 at 6:27 PM | investing.comUltragenyx and Mereo BioPharma Progress Phase 3 Study of Setrusumab in Pediatric Osteogenesis Imperfecta PatientsJuly 9 at 4:17 PM | quiverquant.comQUltragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final AnalysisJuly 9 at 4:17 PM | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by KBC Group NVJuly 8 at 3:37 AM | marketbeat.comWCM Investment Management LLC Has $7.65 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)July 3, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 3, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 3, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 6.3% - Should You Buy?July 2, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Below 50 Day Moving Average - What's Next?July 1, 2025 | marketbeat.comRARE's GTX-102 Gets FDA's Breakthrough Status for Angelman SyndromeJune 30, 2025 | zacks.comUltragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drugJune 27, 2025 | au.investing.comUltragenyx Gets FDA Designation to Expedite GTX-102 Drug DevelopmentJune 27, 2025 | marketwatch.comUltragenyx Pharmaceutical Inc. Receives FDA Breakthrough Therapy Designation for GTX-102 to Treat Angelman SyndromeJune 27, 2025 | quiverquant.comQUltragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman SyndromeJune 27, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 2,405 SharesJune 24, 2025 | insidertrades.comFDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding IntentJune 23, 2025 | biospace.comBInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells 2,405 Shares of StockJune 23, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Grants 48,731 Restricted Stock Units to Newly Hired Non-Executive OfficersJune 20, 2025 | quiverquant.comQUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comGuggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)June 20, 2025 | marketbeat.comGAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialRigetti Computing: Cantor's Bullish Call May Be Just the StartBy Jeffrey Neal Johnson | July 3, 2025View Rigetti Computing: Cantor's Bullish Call May Be Just the StartBHC, JAZZ, IONS, ASND, and RARE Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$175.71 +7.54 (+4.48%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$175.54 -0.18 (-0.10%) As of 07/9/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Bausch Health Cos NYSE:BHC$6.59 -0.11 (-1.64%) Closing price 07/9/2025 03:57 PM EasternExtended Trading$6.55 -0.04 (-0.61%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Ionis Pharmaceuticals NASDAQ:IONS$42.83 +1.49 (+3.60%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$42.84 +0.01 (+0.01%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Jazz Pharmaceuticals NASDAQ:JAZZ$111.60 +2.47 (+2.26%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$111.80 +0.21 (+0.18%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Ultragenyx Pharmaceutical NASDAQ:RARE$41.44 +2.02 (+5.12%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$33.04 -8.40 (-20.27%) As of 08:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will Oracle's Cloud and AI Deals Propel It to New Highs? Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
